Pfizer Inc. (PFE.DE)
| Previous close | 24.05 |
| Open | 24.09 |
| Bid | 24.11 x 0 |
| Ask | 24.14 x 0 |
| Day's range | 24.03 - 24.25 |
| 52-week range | 23.53 - 37.50 |
| Volume | |
| Avg. volume | 88,086 |
| Market cap | 136.694B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 68.97 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.57 (6.53%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | N/A |
- Reuters
UPDATE 1-US FDA grants full approval for Pfizer's cervical cancer drug
The U.S. Food and Drug Administration (FDA) granted full approval for Pfizer's drug for treating cervical cancer patients whose disease had progressed on or after chemotherapy, the agency said on Monday. The treatment, Tivdak - an antibody-drug conjugate co-developed by Genmab A/S and Seagen - received the FDA's accelerated approval for the same indication in 2021. It was added to Pfizer's oncology portfolio last year through a $43 billion deal to acquire Seagen, along with other targeted cancer therapies.
- Insider Monkey
13 Best Reddit Stocks to Buy Now
In this article, we will take a detailed look at the 13 Best Reddit Stocks to Buy Now. For a quick overview of such stocks, read our article 5 Best Reddit Stocks to Buy Now. Millions of young retail investors turn to Reddit every day to talk or learn about the stock market. Back in the pandemic days, the […]
- Zacks
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Pfizer (PFE) expects its operational revenues to improve, driven by its in-line products like Vyndaqel, new launches like Abrysvo and newly acquired products, including those acquired from Seagen.
